Phase I Study of Autologous Acute Myelogenous Leukemia (AML) Cells Containing Lentivirus Engineering

  • Posted on: 11 March 2016
  • By: admin

This is a phase 1 study (the first stage in testing a new treatment to see how safe and tolerable the treatment is) which will include patients with acute myeloid leukemia (AML) that has either returned or has a more than a 70% chance of coming back and cannot have a bone marrow transplant.

This study will see whether modifying a patient's AML cells to produce IL-12 and giving it back to the patient is safe and useful in patients with AML that cannot have bone marrow transplants.

Sponsor: 
In-House
NCT#: 
NCT02483312
Eligible Tumour Types: 
Acute Myeloid Leukemia (AML)
Recruiting Status: 
Currently Recruiting
Principal Investigator: 
Dr Mark Minden